Educational Objectives

 Explain the pathogenesis of dyslipidemia in the difficult-to-treat patient.

 Discuss the occurrence of dyslipidemia in patients receiving solid
 organ transplants including kidney, liver and heart, and in patients
 after percutaneous coronary intervention.

 Discuss the occurrence of dyslipidemia in patients with primary
 disorders such as diabetes, thyroid disease, HIV, and alcoholic
 and non-alcoholic liver disease.

 Explain the guidelines including the NCEP ATP III, National Kidney
 Foundation (NKF) and American Diabetes Association (ADA) for
 the treatment of dyslipidemia in the difficult-to-treat patient.

 Discuss clinical trial data in patients with difficult-to-treat dyslipidemia
 including the Heart Protection Study (HPS); the Lescol Intervention
 Prevention Study (LIPS); and Assessment of Lescol in Renal
 Transplantation (ALERT).

 Explain and select the appropriate medical management for
 dyslipidemia in the difficult-to-treat patient based on published peer-
 reviewed clinical trial data.

Subject Content

 HDL and lipoprotein metabolism.

 Pharmacokinetics of statins and other lipid-modifying therapies,
 efficacy, and related safety and drug interaction issues.

 Utilization of NCEP ATP III, National Kidney Foundation (NKF) and
 American Diabetes Association (ADA) Guidelines in the assessment
 of global risk for CHD in the difficult-to-treat patient with dyslipidemia.

 Utilization of inflammatory markers in the assessment of risk for CHD
 on the difficult-to-treat patient with dyslipidemia.

This edition is for information and study purposes only as the
CME credits have expired.

Back to Complex Lipid Management